Aignostics Collaborates with Mayo Clinic for New Pathology Model
The model was developed in just two months and sets a new industry standard for performance and efficiency.
Today, Aignostics announced remarkable research results for an innovative pathology foundation model developed in collaboration with Mayo Clinic Digital Pathology. This advanced model was built in a remarkably short period of two months, utilizing 1.2 million diverse slide images sourced from Mayo Clinic and Charité – Universitätsmedizin Berlin. This collaboration has established a new state-of-the-art in performance, excelling across over twenty public benchmarks.
The computational efficiency of this model enhances its usability compared to existing image-based models. Aignostics’ pathologist-curated development approach played a significant role in this high level of performance. By integrating expert medical knowledge throughout the model's development, Aignostics ensures that the final product is not only high-performing but also relevant to current medical needs.
Maximilian Alber, CTO of Aignostics, expressed his excitement about the project: "These results represent an exciting achievement in our collaboration with Mayo Clinic. Together, we have direct access to millions of additional training images and new data modalities that we plan to integrate into the model over time, further enhancing its capabilities and accuracy." This level of collaboration highlights the practical benefits of pooling expertise and resources in the name of medical advancement.
Healthcare and life sciences organizations are expected to extensively use the new model for both research and clinical development. Furthermore, Aignostics is committed to integrating this model into its expanding suite of AI-powered pathology products. These products aim to provide accurate and generalizable solutions across various applications, including biomarker, cell, and tissue image analysis. This comprehensive approach of both licensing foundational technology and offering bespoke applications ensures that partner organizations can effectively leverage the model's capabilities to suit their specific needs.
In reaction to the collaboration, Jim Rogers, CEO of Mayo Clinic Digital Pathology, stated, "Mayo Clinic Digital Pathology will work with Aignostics to transform pathology for the benefit of patients everywhere." The partnership underscores the real potential that exists by combining the vast medical expertise of Mayo Clinic with Aignostics’ pioneering technologies. Viktor Matyas, CEO of Aignostics, added that these results demonstrate their ambition to jointly lead in this burgeoning field.
About Aignostics
Aignostics is an innovative artificial intelligence company focused on transforming complex pathology data into actionable insights. By leveraging proprietary multimodal clinical data, cutting-edge technologies, and robust scientific methodology, Aignostics crafts best-in-class products and services tailored for the future of precision medicine. Through strategic collaborations with biopharma partners, Aignostics supports critical areas such as drug discovery, translational research, clinical trials, and companion diagnostics (CDx) development. Established in 2018, this company emerged as a spin-off from Charité Berlin, one of the largest and most prestigious university hospitals worldwide. Aignostics is backed by prominent investors and maintains operations in both Berlin and New York.
Contact Information
For further inquiries, please reach out to Lisa Zheng.
Frequently Asked Questions
What is the primary focus of Aignostics?
Aignostics primarily focuses on transforming complex pathology data into actionable insights through artificial intelligence.
How long did it take to develop the new pathology model?
The new pathology model was developed in just two months, showcasing a rapid innovation process.
Who were the collaborators in this project?
Aignostics collaborated with the Mayo Clinic Digital Pathology for developing this breakthrough pathology model.
What are the applications of the new pathology model?
The model can be used for research and clinical development in healthcare and life sciences.
What does Aignostics aim to achieve with this model?
Aignostics aims to provide accurate, generalizable solutions for image analysis in pathology, enhancing overall clinical outcomes.
